Xbrane Biopharma Future Growth
Future criteria checks 6/6
Xbrane Biopharma is forecast to grow earnings and revenue by 130.2% and 61.1% per annum respectively. EPS is expected to grow by 135.8% per annum. Return on equity is forecast to be 59% in 3 years.
Key information
130.2%
Earnings growth rate
135.8%
EPS growth rate
Biotechs earnings growth | 44.6% |
Revenue growth rate | 61.1% |
Future return on equity | 59.0% |
Analyst coverage | Low |
Last updated | 28 Oct 2024 |
Recent future growth updates
Recent updates
Even With A 30% Surge, Cautious Investors Are Not Rewarding Xbrane Biopharma AB (publ)'s (STO:XBRANE) Performance Completely
Sep 30Market Cool On Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Pushing Shares 34% Lower
Aug 05Market Might Still Lack Some Conviction On Xbrane Biopharma AB (publ) (STO:XBRANE) Even After 32% Share Price Boost
Jun 21Is Xbrane Biopharma (STO:XBRANE) In A Good Position To Deliver On Growth Plans?
Jun 04We Think Xbrane Biopharma (STO:XBRANE) Needs To Drive Business Growth Carefully
Nov 05Market Sentiment Around Loss-Making Xbrane Biopharma AB (publ) (STO:XBRANE)
Mar 24Xbrane Biopharma AB (publ) (STO:XBRANE) Insiders Increased Their Holdings
Mar 02Xbrane Biopharma AB (publ)'s (STO:XBRANE) Intrinsic Value Is Potentially 28% Above Its Share Price
Feb 10We Think Xbrane Biopharma (STO:XBRANE) Can Afford To Drive Business Growth
Jan 12Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 844 | 550 | N/A | N/A | 2 |
12/31/2025 | 460 | 40 | N/A | 33 | 2 |
12/31/2024 | 299 | -176 | N/A | -74 | 1 |
9/30/2024 | 200 | -305 | -344 | -309 | N/A |
6/30/2024 | 192 | -341 | -431 | -419 | N/A |
3/31/2024 | 191 | -361 | -465 | -463 | N/A |
12/31/2023 | 239 | -322 | -423 | -407 | N/A |
9/30/2023 | 189 | -285 | -467 | -441 | N/A |
6/30/2023 | 144 | -246 | -427 | -390 | N/A |
3/31/2023 | 112 | -189 | -340 | -296 | N/A |
12/31/2022 | 58 | -169 | -254 | -194 | N/A |
9/30/2022 | 43 | -146 | -216 | -139 | N/A |
6/30/2022 | 32 | -147 | -229 | -127 | N/A |
3/31/2022 | 15 | -172 | -282 | -182 | N/A |
12/31/2021 | 11 | -183 | -297 | -220 | N/A |
9/30/2021 | 8 | -213 | -278 | -227 | N/A |
6/30/2021 | 5 | -219 | -286 | -268 | N/A |
3/31/2021 | 3 | -215 | -160 | -147 | N/A |
12/31/2020 | N/A | -218 | -242 | -238 | N/A |
9/30/2020 | N/A | -222 | -169 | -165 | N/A |
6/30/2020 | N/A | -210 | -146 | -145 | N/A |
3/31/2020 | N/A | -204 | -180 | -179 | N/A |
12/31/2019 | N/A | -188 | -150 | -149 | N/A |
9/30/2019 | 5 | -154 | -118 | -117 | N/A |
6/30/2019 | 7 | -56 | 0 | 2 | N/A |
3/31/2019 | 12 | -40 | 0 | 2 | N/A |
12/31/2018 | 20 | -13 | 45 | 47 | N/A |
9/30/2018 | 25 | 0 | -8 | -4 | N/A |
6/30/2018 | 23 | -69 | N/A | -47 | N/A |
3/31/2018 | 23 | -45 | N/A | -36 | N/A |
12/31/2017 | 21 | -45 | N/A | -37 | N/A |
9/30/2017 | 11 | -35 | N/A | -35 | N/A |
6/30/2017 | 11 | -34 | N/A | -39 | N/A |
3/31/2017 | 6 | -31 | N/A | -41 | N/A |
12/31/2016 | N/A | -28 | N/A | -39 | N/A |
9/30/2016 | 0 | -24 | N/A | -37 | N/A |
6/30/2016 | 0 | -19 | N/A | -27 | N/A |
3/31/2016 | 1 | -16 | N/A | -19 | N/A |
12/31/2015 | 0 | -12 | N/A | -12 | N/A |
9/30/2015 | 2 | -8 | N/A | -5 | N/A |
12/31/2014 | 2 | -3 | N/A | -3 | N/A |
12/31/2013 | 0 | -2 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XBRANE is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).
Earnings vs Market: XBRANE is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: XBRANE is expected to become profitable in the next 3 years.
Revenue vs Market: XBRANE's revenue (61.1% per year) is forecast to grow faster than the Swedish market (1.3% per year).
High Growth Revenue: XBRANE's revenue (61.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: XBRANE's Return on Equity is forecast to be very high in 3 years time (59%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 11:48 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Xbrane Biopharma AB (publ) is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
John Savin | Edison Investment Research |
Hans Mähler | Nordea Markets |
null null | Nordea Markets |